Antimutagenic structural modification of quinoline assessed by an in vivo mutagenesis assay using lacZ-transgenic mice

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 414, Issue 1-3, 1998, Pages 165-169

  Miyata, Yuko ^a   Saeki, Ken Ichi ^a   Kawazoe, Yutaka ^a   Hayashi, Makoto ^b   Sofuni, Toshio ^b   Suzuki, Takayoshi ^b  

^a NAGOYA CITY UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Antimutagenesis; Fluorine substitution; In vivo mutation; Muta(TM)Mouse; Quinoline; Transgenic mouse

Indexed keywords

QUINOLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOASSAY; DRUG EFFECT; GENOTOXICITY; LIVER CANCER; LIVER MICROSOME; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; BONE MARROW; LAC OPERON; LIVER; MALE; MICE; MICE, TRANSGENIC; MICRONUCLEUS TESTS; MUTAGENICITY TESTS; QUINOLINES; TESTIS;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS MUSCULUS;

EID: 0032507680     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(98)00029-1     Document Type: Article

References (22)

1. Hirao K., Shinohara Y., Tsuda H., Fukushima S., Takahashi M., Ito N. Carcinogenic activity of quinoline on rat liver. Cancer Res. 36:1976;329-335.
2. Shinohara Y., Ogiso T., Hananouchi M., Nakanishi K., Yoshimura T., Ito N. Effect of various factors on the induction of liver tumors in animals by quinoline. Jpn. J. Cancer Res. 68:1977;785-796.
3. Wayand E.H., Defauw J., McQueen C.A., Meschter C.L., Meegalla S.K., LaVoie E.J. Bioassay of quinoline, 5-fluoroquinoline, carbazole, 9-methylcarbazole and 9-ethylcarbazole in newborn mice. Food Chem. Toxicol. 31:1993;707-715.
4. Nagao M., Yahagi T., Seino Y., Sugimura T., Ito N. Mutagenicities of quinoline and its derivatives. Mutat. Res. 42:1977;335-342.
5. Takahashi K., Kamiya M., Sengoku Y., Kohda K., Kawazoe Y. Deprivation of the mutagenic property of quinoline: inhibition of mutagenic metabolism by fluorine substitution. Chem. Pharm. Bull. 36:1988;4630-4633.
6. M. Kamiya, Y. Sengoku, K. Takahashi, K. Kohda, Y. Kawazoe, Antimutagenic structure modification of quinoline: fluorine-substitution at position-3, in: Y. Kuroda, D.M. Shankel, M.D. Waters (Eds.), Antimutagenesis and Anticarcinogenesis, Vol. II, 1990, pp. 441-446.
7. Tada M., Takahashi K., Kawazoe Y. Binding of quinoline to nucleic acid in a subcellular microsomal system. Chem.-Biol. Interactions. 29:1980;257-266.
8. Tada M., Takahashi K., Kawazoe Y. Metabolites of quinoline, a hepatocarcinogen, in a subcellular microsomal system. Chem. Pharm. Bull. 30:1982;3834-3837.
9. Saeki K., Takahashi K., Kawazoe Y. Metabolism of mutagenicity-deprived 3-fluoroquinoline: comparison with mutagenic quinoline. Biol. Pharm. Bull. 16:1993;232-234.
10. Saeki K., Kawai H., Kawazoe Y., Hakura A. Dual stimulatory and inhibitory effects of fluorine-substitution on mutagenicity: an extension of the enamine epoxide theory for activation of the quinoline nucleus. Biol. Pharm. Bull. 20:1997;646-650.
11. LaVoie E.J., Tulley-Freiler L., Bedenko V., Hoffmann D. Mutagenicity of substituted phenanthrenes in Salmonella typhinurium. Mutat. Res. 116:1983;91-102.
12. Hecht S.S., LaVoie E.J., Bedenko V., Pingaro L., Katayama S., Hoffmann D., Sardella D.J., Boger E., Lehr R.E. Reduction of tumorigenicity and of dihydrodiol formation by fluorine substitution in the angular rings of dibenzo[a,i]pyrene. Cancer Res. 41:1981;4341-4345.
13. Hubenman E., Slag T.J. Mutagenicity and tumor-initiating activity of fluorinated derivatives of 7,12-dimethylbenz[a]anthracene. Cancer Res. 39:1979;411-414.
14. Diamond L., Chain K., Harvey R.G., DiGiovanni J. Mutagenic activity of methyl- and fluoro-substituted derivatives of polycyclic aromatic hydrocarbons in a human hepatoma cell-mediated assay. Mutat. Res. 136:1984;65-72.
15. Miller E.C., Miller J.A. The carcinogenicity of fluoro derivatives of 10-methyl-1,2-benzanthracene: 3- and 4-monofluoro derivatives. Cancer Res. 20:1960;133-137.
16. Saeki K., Kadoi M., Kawazoe Y., Futakuchi M., Tiwawech D., Shirai T. Modification of the carcinogenic property of quinoline, a hepatocarcinogen, by fluorine atom substitution: evaluation of carcinogenicity by a medium-term assay. Biol. Pharm. Bull. 20:1997;40-43.
17. Ito N., Tsuda H., Tatematsu M., Inoue T., Tagawa Y., Aoki T., Uwagawa S., Kagawa M., Ogiso T., Masui T., Imaida K., Fukushima S., Asamoto M. Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats: an approach for a new medium-term bioassay system. Carcinogenesis. 9:1988;387-394.
18. T. Suzuki, Y. Miyata, K. Saeki, Y. Kawazoe, M. Hayashi, T. Sofuni, In vivo mutagenesis by the hepatocarcinogen quinoline in the lacZ transgenic mouse: evidence for its in vivo genotoxicity, Mutat. Res., 1998, in press.
19. Araki M., Saneyoshi M., Harada H., Kawazoe Y. Synthesis and reactions of 3-fluoro-4-nitroquinoline 1-oxide. Chem. Pharm. Bull. 16:1968;1742-1746.
20. Collaborative study group organized by T. Susuki Organ variation in the mutagenicity of ethylnitrosourea in Muta™Mouse: results of the collaborative study on the transgenic mutation assay by JEMS/MMS. Environ. Mol. Mutagen. 28:1996;363-375.
21. Suzuki T., Itoh T., Hayashi M., Nishikawa S., Ikezaki F., Furukawa M., Takahashi M., Sofuni T. Organ variation in the mutagenicity of dimethylnitrosamine in Big Blue® mice. Environ. Mol. Mutagen. 28:1996;348-353.
22. Hayashi M., Morita T., Sofuni T., Ishidate M. Jr. The micronucleus assay with mouse peripheral blood reticulocytes using acridine orange-coated slides. Mutat. Res. 245:1990;245-249. and references cited therein.